Clinical Trials Logo

Follicular Lymphoma (FL) clinical trials

View clinical trials related to Follicular Lymphoma (FL).

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04796922 Withdrawn - Clinical trials for Marginal Zone Lymphoma (MZL)

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Start date: December 30, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study of parsaclisib plus investigator's choice of either rituximab or obinutuzumab versus placebo plus investigator's choice of rituximab or obinutuzumab for the treatment of participants with R/R FL or MZL. The Participants will be stratified in a 1:1 randomization ratio by investigator's choice of rituximab or obinutuzumab prior to randomization, time since last antilymphoma therapy (≤ 2, > 2 years), and disease histology (MZL or FL) .